Akeso's Ivonescimab Phase III Trial Beats AstraZeneca's Imfinzi
Nashnova编辑部
Akeso's bispecific antibody ivonescimab significantly beat AstraZeneca's Imfinzi on overall survival in a phase III biliary tract cancer trial — the drug's second pivotal readout after lung cancer — sending licensee Summit Therapeutics shares higher pre-market.
What did this trial test?
HARMONi-GI1 is a phase III trial run in China. It compared two first-line regimens for advanced biliary tract cancer — cancer of the liver ducts and gallbladder area.
Experimental arm: ivonescimab + chemotherapy. Control arm: AstraZeneca's durvalumab (Imfinzi) + chemotherapy.
The primary endpoint was overall survival (OS) — time from enrollment to death. This means → the trial answered the hardest question in oncology: "Which regimen keeps patients alive longer?"
What were the results?
The ivonescimab arm achieved a statistically significant and clinically meaningful improvement in overall survival over the Imfinzi arm.
Both key secondary endpoints were also met: progression-free survival (PFS) — how long before tumors start growing again — and objective response rate (ORR) — the share of patients whose tumors shrank meaningfully.
In plain terms = all three core efficacy measures beat the comparator. That is uncommon in oncology trials — many drugs win on one or two, not all three.
What is ivonescimab?
Ivonescimab is a bispecific antibody — a single molecule engineered to bind two different targets at once — developed by Akeso (康方生物, AKESF).
Summit Therapeutics (SMMT) holds the license for markets outside China. This means → Akeso contributes the science and China trial data; Summit owns the ex-China commercial rights — a typical Chinese biotech out-licensing model.
This biliary tract readout is ivonescimab's second pivotal phase III dataset, following earlier lung cancer trials. The drug's clinical evidence base is broadening.
Why does the market care?
Summit Therapeutics shares rose pre-market, a direct read on how investors received the data.
This reflects a bigger question investors are tracking: whether ivonescimab can accumulate enough multi-indication data to advance regulatory filings and win approvals — the real unlock for its commercial potential.
Full data have not yet been released. Summit said details will be presented at a future medical conference and submitted for peer-reviewed publication. Put simply = what we have now is a top-line readout from a pre-specified interim analysis — the direction is clear, but the market still needs the complete dataset.
市场有风险，内容仅供研究参考，不构成投资建议。